Fox Run Management L.L.C. Boosts Stake in Solventum Corporation $SOLV

Fox Run Management L.L.C. boosted its stake in Solventum Corporation (NYSE:SOLV) by 72.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,646 shares of the company’s stock after buying an additional 7,821 shares during the quarter. Fox Run Management L.L.C.’s holdings in Solventum were worth $1,478,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. LSV Asset Management lifted its stake in Solventum by 364.5% in the 3rd quarter. LSV Asset Management now owns 35,122 shares of the company’s stock valued at $2,564,000 after buying an additional 27,561 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Solventum by 15.3% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock worth $22,469,000 after purchasing an additional 40,812 shares during the period. Davis Selected Advisers lifted its stake in shares of Solventum by 0.5% during the 3rd quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after purchasing an additional 24,950 shares during the period. Appleton Partners Inc. MA purchased a new position in shares of Solventum during the 4th quarter worth $7,008,000. Finally, SG Americas Securities LLC lifted its stake in shares of Solventum by 92.3% during the 4th quarter. SG Americas Securities LLC now owns 93,681 shares of the company’s stock worth $7,423,000 after purchasing an additional 44,970 shares during the period.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of recent analyst reports. UBS Group lowered Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Thursday, May 14th. Rothschild & Co Redburn initiated coverage on Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 price target on the stock. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. KeyCorp increased their price target on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Wells Fargo & Company reduced their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and a consensus price target of $84.25.

Solventum Trading Down 2.8%

SOLV stock opened at $78.70 on Tuesday. The company has a market cap of $13.63 billion, a price-to-earnings ratio of 9.64, a PEG ratio of 1.25 and a beta of 0.69. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The business has a fifty day simple moving average of $71.19 and a 200-day simple moving average of $75.21. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.